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Abstract: Many patients with advanced cancer experience decreased bone strength due to 
metastatic foci, underlying osteoporosis and/or cancer treatment induced bone loss. The clinical 
consequences of metastatic disease involving the skeleton are widespread. This review focuses on 
the efﬁ  cacy, pharmacology, and safety when using intravenous biphosphonate such a zoledronic 
acid for cancer bone metastases. Zoledronic acid is the gold standard for the medical manage-
ment of metastatic bone disease. The indications for treatment include prevention of skeletal 
relevant events (SRE), osteoporotic complications, and palliation of bone pain, among others. 
Zoledronic acid is the only bisphosphonate effective in decreasing SREs associated with bone 
metastases from advanced renal cell carcinoma and prostate cancer. Regarding prostate cancer, 
zoledronic acid effectively prevents both bone loss in patients with locally advanced disease 
receiving androgen deprivation therapy and SREs in men with hormone-refractory or hormone-
sensitive metastatic disease. Zoledronic acid has an acceptable safety proﬁ  le and tolerability, 
and has been effective at signiﬁ  cantly decreasing the incidence, delaying the onset, and reduc-
ing the overall risk of experiencing an SRE compared to placebo. It is the only bisphosphonate 
currently approved for the prevention and treatment of skeletal complications in patients with 
bone metastases due to all solid tumors.
Keywords: zoledronic acid, metastatic bone disease, osteoporosis, skeletal relevant events, advanced 
prostate cancer
Introduction to management of metastatic bone 
disease
Many patients with advanced cancer experience decreased bone strength due to meta-
static foci, underlying osteoporosis, and/or cancer-treatment-induced bone loss. Patients 
at risk of bone loss include smokers, those with excessive alcohol use, low calcium 
intake, sedentary lifestyle, and hypogonadal men. Osteoporosis affects approximately 
75 million people in Europe, the United States, and Japan (International Osteoporo-
sis Foundation 2007). Although the focus of development of osteoporosis has been 
associated with aging women, it has only recently been appreciated that men remain 
at high risk for osteoporosis, as the National Osteoporosis Foundation estimates that 
2 million American men have the disease and is increasing. Androgen deprivation 
therapy, which is commonly employed therapeutically in advanced prostate cancer, 
increases bone loss and subsequent fracture risk (Daniell et al 1997).
The potential consequences of metastatic cancer affecting the skeleton are multiple. 
First, it often signals a signiﬁ  cant change in quality of life as patients are more likely 
to develop skeletal fractures, bone pain, hypercalcemia of malignancy, or spinal cord 
compression. Second, extensive bone metastases accompany poor health and dimin-
ished survival (Soloway et al 1988; Sabbatini et al 1999). Third, skeletal-related events 
(SREs) invariably accompany waning quality of life. Fractures diminish quality of life, 
and even unrecognized fracture can cause functional impairment, decreased mobility Therapeutics and Clinical Risk Management 2008:4(1) 262
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or pain. Patients with bone metastases are at increased risk 
of mortality as the ultimate demise of the patient often is 
coupled to skeletal complications (Coleman et al 2005).
The more common human cancers metastasizing to bone 
are breast, prostate, multiple myeloma, and kidney. The inci-
dence of multiple myeloma in the United States is estimated 
at 15,000 annually, and these malignant plasma cells usually 
attack bone structure causing osteolytic lesions. In regards 
to breast cancer, bone is the most common site of distant 
disease recurrence and is estimated to affect up to 75% of 
women with advanced breast cancer (Coleman et al 2001). 
Of those with bone metastasis, two-thirds will develop a SRE 
(Plunkett et al 2000). The median survival with advanced 
breast cancer is about 18–26 months after diagnosis of bone 
metastasis, placing women at risk of skeletal complications 
(Coleman et al 2001). Approximately one-third of patients 
with advanced renal cell carcinoma develop bone metastases. 
However once this occurs the 2-year survival rate decreases 
to 10%–20% with a median survival of 1 year (Flanigan et al 
2003; Martel et al 2003). The natural history of untreated 
patients with prostate cancer and bone metastases show that 
almost 50% had experienced at least one SRE by 2 years, 
the majority of which comprised a pathologic fracture(s) or 
need for palliative radiation (Saad et al 2004). Greater than 
80% of men dying of prostate cancer have autopsy-proven 
bone metastases (Harada et al 1992).
In contrast to bone lesions secondary to metastatic breast 
cancer, the majority of lesions from metastatic prostate can-
cer are osteoblastic. Interestingly, the dysregulated process 
of bone turnover when affected by cancer invasion also 
includes increased osteolysis (Garnero et al 2000). Since 
the process of bone homeostasis is impaired, the new bone 
deposited under the inﬂ  uence of metastatic cancer cells is 
poorly mineralized with less integrity. This process increases 
the risk of a subsequent SRE. Most bone metastases due to 
renal cell carcinoma are predominantly osteolytic. Of those 
patients with renal cell carcinoma with bone metastases, 
approximately one-third of patients develop hypercalcemia 
of malignancy, half developed long-bone fracture, and the 
majority required palliative radiation for pain (Zekri et al 
2001; Rosen et al 2004a).
Regarding advanced prostate cancer, many men with 
bone metastases are treated with androgen deprivation 
therapy which represents the standard of care for metastatic 
disease. Older age, long duration of androgen deprivation 
therapy, and low body mass index are risk factors for 
increased bone loss during androgen deprivation therapy in 
men with locally advanced disease. Patients with prostate 
cancer receiving androgen deprivation therapy are at risk of 
skeletal complications, regardless of disease stage.
The clinical consequences of metastatic disease involv-
ing the skeleton are widespread. Of all the bisphosphonate 
agents available, zoledronic acid is the only agent demon-
strated to effectively reduce SREs and delay their onset in 
patients with advanced renal or prostate cancer metastatic to 
bone. This review will discuss the efﬁ  cacy, pharmacology, 
and safety when using zoledronic acid to treat metastatic 
disease of the bone.
Pharmacology of zoledronic acid
Normal bone turnover involves a complex interaction 
between bone breakdown and bone turnover that is 
typically in equilibrium. Osteoclasts decompose bone 
matrix and mineral, allowing mononuclear cells to 
prepare bone surface for osteoblasts. In turn, osteoblasts 
lay down new matrix and bone substance. Estrogens and 
androgens help provide the milieu to maintain normal bone 
turnover. During the process of metastases, cancer cells 
create dysregulated bone turnover, with varying degrees 
of impaired osteolysis and bone synthesis seen depending 
on the type of cancer. For example, mixed osteoblastic and 
osteolytic metastases are commonly found in both prostate 
and breast cancer.
Bisphosphonates are pyrophosphate analogues that bind 
to hydroxyapatite, accumulate in bone and inhibit osteoclastic 
activity. As a class, bisphosphonates have several modes 
of action on osteoclasts. They preferentially bind to bone 
surfaces undergoing active remodeling. These agents are 
selectively adsorbed into mineral surfaces on bone that are 
surrounded by osteoclasts and are then released, whereby they 
are internalized by and disrupt the bone-resorbing action of 
osteoclasts (Lipton 2004). Osteoclast maturation is inhibited 
and apoptosis is induced. Bisphosphonates suppress osteo-
clast activity and inhibit osteoclast recruitment to sites of 
bone resorption. Finally, they decrease bone resorbing growth 
factor and cytokine production. There is some evidence that 
bisphosphonates may also inhibit cancer cell-bone matrix 
binding, inhibiting invasion of cancer into the bone (Boissier 
et al 1997, 2000).
Zoledronic acid is a third generation nitrogen-containing 
bisphosphonate. Its core bisphosphonate moiety attaches 
to bone while its imidazole ring containing two nitrogen 
atoms conﬁ  rms its potency. Zoledronic acid is approximately 
100-fold more potent than pamidronate (Green et al 1994). 
Bisphosphonates have low intestinal absorption and can 
cause esophageal mucosal irritation if taken orally. For this Therapeutics and Clinical Risk Management 2008:4(1) 263
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reason, the formulated intravenous product is well absorbed 
and remains active in bone for some time.
Efﬁ  cacy in metastatic disease
The propensity of cancer to metastasize to bone is governed 
by ligand-receptor interactions between the host site and the 
cancer cell type. Tumor cell surface adhesion molecules, such 
as the chemokine receptor CXCR4-stromal derived factor 
(SDR-1) interaction, the integrins, and the matrix metallo-
proteinases are thought to mediate skeletal targeting.
Zoledronic acid is the current standard of care for treating 
bone metastases from hormone-refractory prostate cancer, 
advanced breast cancer, stage III multiple myeloma and 
advanced renal cancer. In advanced breast cancer, randomized 
trials have demonstrated zoledronic acid to signiﬁ  cantly 
delay the onset and decrease the incidence of SREs when 
used in conjunction with chemotherapy or hormonal therapy 
(Kristensen et al 1999; Lipton et al 2000; Body et al 2003, 
2004; Rosen et al 2004b). In a randomized, double-blind, 
phase III study, 1640 patients with breast cancer or multiple 
myeloma and at least one bone lesion were relegated to 
zoledronic acid or palmidronate for a 2-year period. Overall, 
zoledronic acid was superior to palmidronate, the prior 
standard of care agent, in decreasing overall risk of developing 
SREs by 16% at 2 years (Rosen et al 2001). Of those patients 
with advanced breast cancer and a minimum of one osteolytic 
lesion, the median time to ﬁ  rst SRE was signiﬁ  cantly longer 
when administered zoledronic acid compared to pamidronate 
(310 vs 174 days, p  =  0.013). Zoledronic acid was signiﬁ  cantly 
more effective than palmidronate by decreasing the risk of 
SREs by an additional 20% compared to palmidronate and 
by an additional 30% in those receiving hormonal therapy 
(Rosen et al 2001). In a Japanese randomized trial of 228 
breast cancer patients with bone metastases, zoledronic acid 
treated women showed a signiﬁ  cant reduction of 39% in SREs 
(p = 0.027) when compared to placebo (Kohno et al 2005). 
Zoledronic acid also demonstrated signiﬁ  cantly longer time 
to ﬁ  rst skeletal complication (median not reached vs 364 days 
placebo, p = 0.007).
The efficacy of treating skeletal complications of 
advanced renal cell carcinoma was demonstrated in a subset 
of 46 kidney cancer patients in a large phase III placebo-
controlled trial also involving lung cancer and other solid 
tumors (Rosen et al 2004b). In this study, most patients (81% 
zoledronic acid vs 95% placebo) had already experienced a 
SRE before entry. Despite this, zoledronic acid signiﬁ  cantly 
delayed the time to subsequent SRE in the study by nearly 
12 months compared to placebo, and signiﬁ  cantly reduced 
the incidence of SREs. Overall the risk of developing a SRE 
in renal cell carcinoma patients with bone metastases was 
reduced by 58% when compared to placebo.
In a randomized, double blind, placebo controlled study of 
643 men with metastatic hormone-refractory prostate cancer, 
zoledronic acid (4 mg IV q 3 wk) signiﬁ  cantly reduced the 
percentage of patients experiencing SREs compared with 
placebo at 15 (33.2% vs 44.2%, p = 0.02) and 24 (38% 
vs 49%, p = 0.028) months (Saad et al 2004). The median 
time to the onset of the ﬁ  rst SRE was delayed by more than 
5 months (488 vs 321 days; p = 0.009) (Saad et al 2002, 
2004). Zoledronic acid decreased the overall risk of skeletal 
complications by 36% at 24 months (p = 0.002) (Saad et al 
2004). Although study patients reported increasing bone pain 
throughout the clinical trial, changes in the Brief Pain Index 
(BPI) score were signiﬁ  cantly lower in patients receiving 
zoledronic acid compared to placebo (p   0.05 by 21 months) 
(Saad et al 2004). This suggests a durable reduction in bone 
pain in zoledronic acid-treated patients with metastatic 
prostate cancer.
Signiﬁ  cant and sustained reductions in bone pain and 
related complications were achieved using intermittent zole-
dronic acid for as long as 2 years (Saad et al 2002, 2004). In 
comparison, studies evaluating the role of other bisphospho-
nates to reduce bone pain and SREs were more modest. For 
example, pamidronate, a second generation bisphosphonate, 
did not signiﬁ  cantly diminish the incidence of SREs or bone 
pain in a combined analysis of two randomized, multicenter, 
double-blind, placebo-controlled trials (Lipton 2004; Small 
et al 2003). In patients with metastatic prostate cancer, the 
ﬁ  rst-generation (non-nitrogen-containing) bisphosphonates 
etidronate and clodronate only provided marginal short-term 
reductions in pain and analgesic use but did not demonstrate 
overall clinical beneﬁ  t (Higano et al 2004; Lipton 2004). A 
similar trend was seen in a phase II trial evaluating the pal-
liative beneﬁ  t of second-line zoledronic acid in breast cancer 
patients with either a SRE or progressive bone metastases 
despite ﬁ  rst-line bisphosphonate therapy. This study of 31 
women initially treated with pamidronate or clodronate dem-
onstrated that signiﬁ  cant improvements in pain control and 
bone turnover markers can be achieved when rescued with 
the more potent bisphosphonate zoledronic acid (Clemons 
et al 2007). In another study comparing zoledronic acid to 
pamidronate in patients with bone metastases from breast 
cancer or multiple myeloma, zoledronic acid signiﬁ  cantly 
decreased the requirement for palliative radiation for bone 
pain compared to palmidronate (19 vs 24% for palmidronate, 
p = 0.037) (Rosen et al 2003).Therapeutics and Clinical Risk Management 2008:4(1) 264
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Routine use of androgen deprivation therapy as a standard 
of care to treat advanced prostate cancer leads to signiﬁ  cant 
bone loss and osteoporosis that may increase the risk of 
skeletal complications especially when compounded by bone 
metastases. Androgen deprivation therapy is being employed 
earlier in the stage of disease, such as biochemical relapse 
without metastatic disease, and is also continued in men who 
develop hormone-refractory disease. Thus, men in general 
are beginning hormonal manipulation earlier in the course 
of disease and remaining on it longer. It has been shown that 
androgen-deprivation associated bone loss in men is greater 
than that observed in postmenopausal women (Higano et al 
2003). Thus long-term treatment with androgen starvation 
has long-term clinical implications. In men receiving andro-
gen deprivation therapy for advanced prostate cancer, bone 
mineral density is decreased by 0.6%–5.3% annually and 
2.3%–6.6% in those with metastatic disease, exceeding by 5- 
to 10-fold the normal bone loss rates compared with healthy 
men and prostate cancer patients not treated with hormones 
(Smith et al 2001; Smith et al 2003; Higano 2004; Casey 
et al 2006; Israeli et al 2006; Michaelson et al 2006; Ryan 
et al 2006). Thus, use of androgen deprivation increases the 
chance of fracture by 7%–45% compared with similar men 
not under hormonal therapy (Shahinian et al 2005; Smith et al 
2005, 2006). The duration of androgen deprivation therapy 
correlates with risk of hip fracture: 20% increased risk in 
the ﬁ  rst 3 years, 45% during years 3–5 and a 95% increase 
in risk if treated with androgen withdrawal for greater than 
5 years (Ross and Small 2002).
Zoledronic acid has been shown to reduce metastasis-
related bone complications in prostate cancer patients with 
progressive disease after treatment of at least one form of 
androgen deprivation therapy (Saad et al 2002, 2004; Casey 
et al 2006). In prostate cancer patients with hormone-
sensitive skeletal metastatic disease receiving androgen 
deprivation therapy, zoledronic acid signiﬁ  cantly increased 
bone mineral density and the median time to ﬁ  rst SRE was not 
reached (Polascik et al 2005). This suggests that zoledronic 
acid prevents bone complications in men with both hormone-
sensitive and hormone-resistant metastatic prostate cancer. 
The National Comprehensive Cancer Network Guidelines on 
Prostate Cancer state that early bisphosphonate therapy of 
all men with prostate cancer treated with androgen depriva-
tion therapy may prevent androgen-deprivation and/or bone 
metastasis related morbidity and improve quality of life 
(NCCN guidelines).
At the present time, zoledronic acid is the only bisphos-
phonate that has been demonstrated to decrease SREs in 
prostate cancer, breast and renal cell carcinoma patients. 
Zoledronic acid has been shown to be effective for treatment 
of bone metastases regardless of whether the bone lesions 
are predominantly osteolytic or osteoblastic. Patients are 
more likely to experience additional skeletal complications 
once the initial SRE has occurred (Saad et al 2004). For this 
reason it is recommended to continue zoledronic acid as a 
means to prevent further fracture or SREs. Currently, stud-
ies are being undertaken in patients with advanced cancer 
to address the use of bisphosphonates for the prevention of 
bone metastases.
Safety and tolerability
Zoledronic acid can be administered safely with good tol-
erability. It is recommended to administer the medication 
intravenously over at least 15 minutes. Patients must be 
adequately hydrated and a serum creatinine level should 
be assessed prior to administration. It is recommended that 
patients take vitamin D and supplemental calcium daily.
The incidence of adverse events occurring in greater than 
10% of patients on zoledronic acid include back pain (12%), 
nausea (14%), fatigue (14%) or arthralgia (20%) (Zometa® 
[package insert] 2006). Fever, vertigo, asthenia, and renal 
tubular necrosis have been observed at a lower incidence. 
Flu-like symptoms, characterized by fever, myalgia, and/or 
fatigue, have been observed in up to 20% of patients but are 
usually associated with the ﬁ  rst administration. Serum cal-
cium levels should also be periodically monitored; however, 
hypocalcemia is rarely observed in patients taking calcium 
supplementation.
Before commencing bisphosphonate therapy, patients 
should be evaluated for renal insufﬁ  ciency. A calculated 
creatinine clearance is used for dose adjustment for patients 
with mild to moderate renal insufﬁ  ciency. Dose adjustments 
are required for those with a baseline creatinine clearance 
less than 60 mL/minute (Table 1). Clinical trials have dem-
onstrated that renal safety of zoledronic acid over time was 
comparable to placebo (Saad et al 2002). Zoledronic acid 
did not impair renal function in patients with renal cell 
carcinoma, a group that is believed to be at a higher risk for 
such occurrence (Rosen et al 2004b). The 4 mg intravenous 
dose has been shown to have a much lower effect on renal 
toxicity than the 8 mg dose used in early studies. In clini-
cal trials evaluating zoledronic acid (4 mg IV q 3 mo) in 
locally advanced prostate cancer, serum creatinine levels 
signiﬁ  cantly increased in fewer than 1% of patients (Smith 
et al 2003; Casey et al 2006; Israeli et al 2006; Michaelson 
et al 2006; Ryan et al 2006). These studies’ results suggest Therapeutics and Clinical Risk Management 2008:4(1) 265
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that renal impairment may be more common in patients with 
shorter infusion times (eg, 5 vs 15 minutes) and dosage inter-
vals (eg, q 3 weeks vs q 3 months). Treatment is withheld if 
further renal impairment occurs and may be resumed when 
serum creatinine levels return to 10% of baseline. Renal 
dysfunction can be prevented and managed with appropriate 
monitoring and intervention.
Osteonecrosis of the jaw (ONJ) is a complication that has 
received much attention since 2003. This condition is deﬁ  ned 
as avascular necrosis resulting from impaired blood supply 
to bone, usually unassociated with infection. It is clinically 
diagnosed by exposed bone in the maxillofacial area, poor 
wound healing, and pain. The etiology and pathogenesis 
remain unclear as of this writing; however, is likely to be 
multifactorial. Risk factors for ONJ include oral infection, 
inﬂ  ammation, or oral surgery, poor dental hygiene, alcohol 
abuse, or concomitant radiation or chemotherapy. Relatively 
few cases have been reported in patients receiving intrave-
nous bisphosphonates. Although ONJ can be diagnosed by 
the lack of healing following 6 weeks of appropriate dental 
care in the absence of osteoradionecrosis or metastatic 
disease to the jaw, no uniform diagnostic criteria have been 
established.
ONJ tends to occur with long exposure to bisphospho-
nates. In largest retrospective study from MD Anderson Can-
cer Center including 4000 patients who received intravenous 
biphosponates the frequency of ONJ was 0.73% overall, 
1.2% in breast cancer and 2.4% in MM (Hoff et al 2006). 
Patients with ONJ have had longer duration of disease and 
received greater doses of biphosponate therapy than patients 
without ONJ.
Prevention and good oral hygiene are important strategies 
to reduce the chance of experiencing ONJ. It is recommended 
that patients have a dental examination and any dental pro-
cedures completed prior to commencing bisphosphonate 
therapy. While on bisphosphonate medication, patients 
should avoid dental surgery, maintain good hygiene, and 
have a routine dental exam every 6 months. For those requir-
ing dental surgery, no data exist as to whether discontinu-
ing bisphosphonates diminishes the risk of ONJ. If ONJ is 
contracted, management is conservative, using appropriate 
antibiotics, oral rinses, and pain control. The prevalence and 
guidelines for preventing and managing ONJ need to be more 
fully characterized.
Since bisphonates may allay pain in addition to stabilizing 
bone density, patients often combine zoledronic acid with 
other pain therapies, such as opioids, radiation therapy, and/or 
chemotherapy (Saad et al 2002). Nonsteroidal anti-inﬂ  am-
matory medication should only be used with caution due to 
the risk of renal impairment (Berenson 2005). Zoledronic 
acid generally decreases the need for additional therapies to 
treat pain over time (Saad et al 2002, 2004). Bisphosphonates 
are generally well tolerated when employed with cytotoxic 
chemotherapy agents.
The long-term safety of bisphosphonates beyond 2 years 
has not been published to date. In patients with metastatic 
prostate cancer, 2 years of zoledronic acid therapy was well 
tolerated (Saad et al 2004). The mean survival of patients 
with advanced cancer and bone metastases usually does not 
extend beyond this interval.
Patient perspectives
Quality of life remains the main focus from the patient 
perspective. The major problem in many advanced cancers, 
particularly prostate, breast, and renal cancer, is related to 
the bone. Up to 70% of patients with advanced prostate 
cancer have or will develop bone metastases. As such, these 
patients are at high risk for skeletal complications. Any skel-
etal-related event, deﬁ  ned as pathologic fracture, spinal cord 
compression, change in antineoplastic therapy (due to pain), 
need for radiation therapy or surgery due to bone disease, or 
development of hypercalcemia of malignancy, will impact 
quality of life due to both the event itself and also the need 
for further therapy.
Bone-related complications from advanced cancer impact 
quality of life by three common mechanisms: bone pain, 
impaired mobility, and pathologic fracture. Fracture risk 
increases with reduced bone mineral density (Faulkner 2000; 
Cummings et al 2002). Regarding the latter, bone fracture 
negatively correlates with patient survival (Oefelein et al 
2002). Pathologic fracture has been demonstrated to increase 
risk of death by 29% in men with hormone-refractory pros-
tate cancer (Saad et al 2005). Most osteoporotic fractures do 
not spontaneously heal and require further treatment. With 
advanced cancer involving bone metastases, patients are 
not uncommonly dependent of strong narcotics to treat the 
debilitating pain of bone lesions or may require palliative 
radiation or systemic radiopharmaceuticals.
Table 1 Dosing zoledronic acid with renal insufﬁ  ciency
Creatinine clearance   Recommended  Amount to be with- 
(mL/min)   dose (mg)  drawn from vial (mL)
 60 4.0    5
50–60 3.5    4.4
40–49 3.3    4.1
30–39 3.0    3.8Therapeutics and Clinical Risk Management 2008:4(1) 266
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A FACT-G (Functional Assessment of Cancer Therapy-
General) study demonstrated what is already suspected – that 
bone complications affect quality of life with resulting 
signiﬁ  cant reduction in emotional, physical, and functional 
domains (Weinfurt et al 2002). In a study of 248 men 
with hormone-resistant prostate cancer metastatic to bone 
with greater than 1 SRE, health-related quality of life was 
measured with EURO-EQ-5D and FACT-G questionnaires 
along with bone pain index interference and intensity scales. 
Every SRE experienced resulted in reductions in multiple 
quality of life domains, and placed greater burden on both 
the patient and the caregiver (Weinfurt et al 2005).
Similarly, treatment with zoledronic acid has also beneﬁ  ted 
women with advanced breast cancer. In a health-related quality 
of life study among patients with breast cancer receiving 
zoledronic acid for metastatic bone disease, investigators 
concluded that prevention of further SRE resulted in an overall 
increase in health-related quality of life (Weinfurt et al 2004). 
In a study of 101 women with breast cancer and at least 1 
bone metastasis treated with hormonal therapy, the European 
Organisation for Research and Treatment of Cancer Quality of 
Life Core Questionnaire 30 (EORTC QLQ-C30) and the Brief 
Pain Inventory (BPI) were used to assess potential beneﬁ  ts 
of zoledronic acid. At end of study, the BPI demonstrated 
signiﬁ  cant reductions in worst pain (p = 0.008), average pain 
within the last week (p = 0.039) and interference with general 
activity (p = 0.012). Overall health status demonstrated a 
signiﬁ  cant median improvement of 8.3% (p = 0.013) and 
emotional, social, and physical functioning also showed 
signiﬁ  cant overall improvement (p = 0.013, 0.005, and 0.043, 
respectively) at end of study (Wardley et al 2005).
Bone complications resulting from bone metastases 
increase health care costs. These additional costs affect 
both the patient and the health care system. An insurance-
based study of US healthcare claims between 1994 and 
2002 showed a difference in total medical costs of over 
US$20,000 per prostate cancer patient with the presence of 
bone metastases compared with those without skeletal lesions 
(McKiernan et al 2004).
In addition, patients should take on the responsibility 
of active participation in their care when possible. Since 
many patients with advanced cancer have or are at risk of 
osteoporosis, it is recommended that patients improve their 
lifestyle by establishing a routine weight-resistance exercise 
routine, limiting alcohol intake, and taking vitamin D and 
calcium supplements. It is noted that vitamin D and calcium 
supplementation alone were not sufﬁ  cient to prevent bone 
loss in the placebo arm of men with advanced prostate cancer 
requiring androgen deprivation therapy (Smith et al 2003). 
For those who use tobacco products, smoking cessation is 
highly recommended. These modiﬁ  cations aid in decreasing 
bone loss in otherwise healthy people at risk of osteoporosis 
(Higano 2004; Wegner 2006).
Conclusions
Zoledronic acid is the gold standard for the medical man-
agement of metastatic bone disease. The indications for 
zoledronic acid include prevention of skeletal events, osteo-
porotic complications, and palliation of bone pain, among 
others. Zoledronic acid is the only bisphosphonate effective 
in decreasing SREs associated with bone metastases from 
advanced renal cell carcinoma and prostate cancer. Regard-
ing prostate cancer, zoledronic acid effectively prevents 
both bone loss in patients with locally advanced disease 
receiving androgen deprivation therapy and SREs in men 
with hormone-refractory or hormone-sensitive metastatic 
disease. Zoledronic acid has an acceptable safety proﬁ  le and 
tolerability, and has been effective at signiﬁ  cantly decreasing 
the incidence, delaying the onset, and reducing the overall 
risk of experiencing an SRE compared with placebo. It is the 
only bisphosphonate currently approved for the prevention 
and treatment of skeletal complications in patients with bone 
metastases due to all solid tumors.
References
Berenson JR. 2005. Recommendations for zoledronic acid treatment of 
patients with bone metastases. Oncologist, 10:52–62.
Body JJ, Diel IJ, Lichinitzer M, et al. 2004. Oral ibandronate reduces the 
risk of skeletal complications in breast cancer patients with metastatic 
bone disease: results from two randomized, placebo controlled phase 
III studies. Br J Cancer, 90:1133–7.
Body JJ, Diel IJ, Lichinitser MR et al. On behalf of the MF 4625 study 
group. 2003. Intravenous ibandronate reduces the incidence of skeletal 
complications in patients with breast cancer and bone metastases. 
Ann Oncol, 14:1399–405.
Boissier S, Ferreras M, Peyruchaud O, et al. 2000. Bisphosphonates inhibit 
breast and prostate carcinoma cell invasion, an early event in the forma-
tion of bone metastases. Cancer Res, 60:2949–54.
Boissier S, Magnetto S, Frappart L, et al. 1997. Bisphosphonates inhibit 
prostate and breast carcinoma cell adhesion to unmineralized and min-
eralized bone extracellular matrices. Cancer Res, 57:3890–4.
Casey R, Love W, Mendoza C, et al. 2006. Zoledronic acid reduces bone loss 
in men with prostate cancer undergoing androgen deprivation therapy. 
Presented at 2006 Multidisciplinary Prostate Cancer Symposium. Febru-
ary 24–26, 2006; San Francisco, Calif. Abstract #184.
Clemons MJ, Dranitsaris G, Ooi WS, et al. 2006. Phase II trial evaluating 
the palliative beneﬁ  t of second-line zoledronic acid in breast cancer 
patients with either a skeletal-related event for progressive bone 
metastases despite ﬁ  rst-line bisphosphonate therapy. J Clin Oncol, 
24:4895–900.
Coleman RE, Major P, Lipton A, et al. 2005. Predictive value of bone 
resorption and formation markers in cancer patients with bone metas-
tases receiving the bisphosphonate zoledronic acid. J Clin Oncol, 
23:4925–35.Therapeutics and Clinical Risk Management 2008:4(1) 267
Zoledronic acid for bone metastasis
Cummings SR, Bates D, Black DM. 2002. Clinical use of bone densitometry: 
scientiﬁ  c review. JAMA, 288:1889–97.
Daniell HW. 1997. Osteoporosis after orchiectomy for prostate cancer. 
J Urol, 157:439–44.
Faulkner KG. 2000. Bone matters: are density increases necessary to reduce 
fracture risk? J Bone Miner Res, 15:183–7.
Flanigan RC, Campbell SC, Clark JI, et al. 2003. Metastatic renal cell 
carcinoma. Curr Treat Options Oncol, 4:385–90.
Garnero P, Buchs N, Zekri J, et al. 2000. Markers of bone turnover for the 
management of patients with bone metastases form prostate cancer. 
Br J Cancer, 82:858–64.
Green JR, Muller K, Jaeggi KA. 1994. Preclinical pharmacology of CGP 
42’446, a new, potent, heterocyclic bisphosphonate compound. J Bone 
Miner Res, 9:745–51.
Harada M, Iida M, Yamaguchi M, et al. 1992. Analysis of bone metastasis 
of prostatic adenocarcinoma in 137 autopsy cases. Adv Exp Med Biol, 
324:173–82.
Higano CS. 2004. Understanding treatments for bone loss and bone metas-
tases in patients with prostate cancer: a practical review and guide for 
the clinician. Urol Clin N Am, 31:331–52.
Higano CS. 2003. Bone loss and the evolving role of bisphosphonate therapy 
in prostate cancer. Urol Oncol, 21:392–8.
Hoff AO, Toth B, Altundag K, et al. 2006 Osteonecrosis of the Jaw in 
Patients Receiving Intravenous Bisphosphonate Therapy. JCO, 
24(suppl 1):8528.
International Osteoporosis Foundation. The facts about osteoporosis and 
its impact [online]. Accessed January 10, 2007. URL: http://www.
iofbonehealth.org/facts.
Israeli RS, Rosenberg S, Saltzstein D, et al. 2006. Bone mineral density in 
patients with prostate cancer undergoing initial androgen-deprivation 
therapy. J Urol, 175(Suppl 4):134. Abstract 410.
Kohno N, Aogi K, Minami H, et al. 2005. Zoledronic acid signiﬁ  cantly 
reduces skeletal complications compared with placebo in Japanese 
women with bone metastases from breast cancer: a randomized, pla-
cebo-controlled trial. J Clin Oncol, 23:3314–21.
Kristensen B, Ejlertsen B, Groenvold M, et al. 1999. Oral clodronate in 
breast cancer patients with bone metastases: a randomized study. 
J Intern Med, 246:67–74.
Lipton A. 2004. Pathophysiology of bone metastases: how this knowledge 
may lead to therapeutic intervention. J Support Oncol, 2:205–213.
Lipton A, Theriault R, Hortobagyi G, et al. 2000. Pamidronate prevents skel-
etal complications and is effective palliative treatment in women with 
breast carcinoma and osteolytic bone metastases: long-term follow-up 
of two randomized controlled trials. Cancer, 88:1082–90.
McKiernan JM, Delea TE, Liss M, et al. 2004. Impact of skeletal complica-
tions on total medical care costs in prostate cancer patients with bone 
metastases. ProcAm Soc Clin Oncol, 23:531, A6057.
Martel CL, Lara PN. 2003. Renal cell carcinoma: current status and future 
directions. Crit Rev Oncol Hematol, 45:177–90.
Michaelson MD, Lee H, Kaufman DS, et al. 2006. Annual zoledronic acid 
to prevent gonadotropin-releasing hormone agonist-induced bone loss 
in men with prostate cancer: a randomized placebo-controlled trial. 
J Clin Oncol, 24(18S pt 1):220s. Abstract #4515.
Oefelein MG, Ricchiuti V, Conrad W, et al. 2002. Skeletal fractures 
negatively correlate with overall survival in men with prostate cancer. 
J Urol, 168:1005–7.
Polascik TJ, Given RW, Metzer C, et al. 2005. Open-label trial evaluating 
the safety and efﬁ  cacy of zoledronic acid in preventing bone loss in 
patients with hormone-sensitive prostate cancer and bone metastases. 
Urology, 66:1054–9.
Plunkett TA, Smith P, Rubens RD. 2000. Risk of complications from 
bone metastases in breast cancer: implications for management. 
Eur J Cancer, 36:476–82.
Rosen LS, Gordon DH, Dugan W, et al. 2004a. Zoledronic acid is 
superior to pamidronate for the treatment of bone metastases in 
breast carcinoma patients with at least one osteolytic lesion. Cancer, 
100:36–43.
Rosen LS, Gordon D, Kaminski M, et al. 2001. Zoledronic acid versus 
palmidronate in the treatment of skeletal metastases in patients with 
breast cancer or osteolytic lesions of multiple myeloma: a phase III, 
double-blind, comparative trial. Cancer, J 7:377–87.
Rosen LS, Gordon D, Kaminski M, et al. 2003. Long-term efﬁ  cacy and 
safety of zoledronic acid compared with pamidronate disodium in the 
treatment of skeletal complications in patients with advanced multiple 
myeloma or breast carcinoma: a randomized, double-blind, multicenter, 
comparative trial. Cancer, 98:1735–44.
Rosen LS, Gordon D, Tchekmedyian NS, et al. 2004b. Long-term efﬁ  cacy 
and safety of zoledronic acid in the treatment of skeletal metastases in 
patients with non-small cell lung carcinoma and other solid tumors: a 
randomized, phase III double-blind, placebo-controlled trial. Cancer, 
100:2613–21.
Ross RW, Small EJ. 2002. Osteoporosis in men treated with androgen 
deprivation therapy for prostate cancer. J Urol, 167:1952–6.
Ryan CW, Huo D, Demers LM, et al. 2006. Zoledronic acid initiated during 
the ﬁ  rst year of androgen deprivation therapy increases bone mineral 
density in patients with prostate cancer. J Urol, 176:972–8.
Saad F, Gleason DM, Murray R, et al. 2002. A randomized, placebo-
controlled trial of zoledronic acid in patients with hormone-refractory 
metastatic prostate carcinoma. J Natl Cancer Inst, 94:1458–68.
Saad F, Gleason DM, Murray R, et al. 2004. Long-term efﬁ  cacy of zole-
dronic acid for the prevention of skeletal complications in patients 
with metastatic hormone-refractory prostate cancer. J Natl Cancer 
Inst, 96:879–82.
Saad F, Lipton A. 2005. Zoledronic acid is effective in preventing and 
delaying skeletal events in patients with bone metastases secondary to 
genitourinary cancers. BJU Internat, 96:964–9.
Sabbatini P, Larson SM, Kremer A, et al. 1999. Prognostic signiﬁ  cance of 
extent of disease in bone in patients with androgen-independent prostate 
cancer. J Clin Oncol, 17:948–57.
Shahinian VB, Kuo YF, Freeman JL, et al. 2005. Risk of fracture after 
androgen deprivation for prostate cancer. N Engl J Med, 352:154–64.
Small EJ, Smith MR, Seaman JJ, et al. 2003. Combined analysis of two 
multicenter, randomized, placebo-controlled studies of pamidronate 
disodium for the palliation of bone pain in men with metastatic prostate 
cancer. J Clin Oncol, 21:427784.
Smith MR, Boyce SP, Moyneur E, et al. 2006. Risk of clinical fractures 
after gonadotropin-releasing hormone agonist therapy for prostate 
cancer. J Urol, 175:136–9.
Smith MR, Eastham J, Gleason DM, et al. 2003. Randomized controlled 
trial of zoledronic acid to prevent bone loss in men receiving andro-
gen deprivation therapy for nonmetastatic prostate cancer. J Urol, 
169:2008–12.
Smith MR, Lee WC, Brandman J, et al. 2005. Gonadotropin-releasing 
hormone agonists and fracture risk: a claims-based cohort study of men 
with nonmetastatic prostate cancer. J Clin Oncol, 23:7897–903.
Smith MR, McGovern FJ, Zietman AL, et al. 2001. Pamidronate to prevent 
bone loss during androgen-deprivation therapy for prostate cancer. 
N Engl J Med, 345:948–55.
Soloway MS, Hardeman SW, Hickey D, et al. 1988. Stratiﬁ  cation of patients 
with metastatic prostate cancer based on extent of disease on initial 
bone scan. Cancer, 61:195–202.
The NCCN (2.2005) Prostate Cancer Clinical Practice Guidelines in 
Oncology© 2006 National Comprehensive Cancer Network, Inc. URL: 
http://www.nccn.org.
Wardley A, Davidson N, Barrett-Lee P, et al. 2005. Zoledronic acid signiﬁ  -
cantly improves pain scores and quality of life in breast cancer patients 
with bone metastases: a randomized, crossover study of community vs 
hospital bisphosphonate administration. Br J Cancer, 92:1869–76.
Wegner H. 2006. Clinical experience with zoledronic acid: a urologist’s 
perspective. Eur Urol Suppl, 5:551–2.
Weinfurt KP, Castel LD, Li Y, et al. 2004. Health-related quality of 
life among patients with breast cancer receiving zoledronic acid or 
palmidronate disodium for metastatic bone lesions. Medical Care, 
42:164–75.Therapeutics and Clinical Risk Management 2008:4(1) 268
Polascik and Mouraviev
Weinfurt KP, Li Y, Castel LD, et al. 2002. The impact of skeletal-related 
events on health-related quality of life of patients with metastatic 
prostate cancer. Ann Oncol, 13:180.
Weinfurt KP, Li Y, Castel LD, et al. 2005. The signiﬁ  cance of skeletal-
related events for the health-related quality of life of patients with 
metastatic prostate cancer. Ann Oncol, 16:579–84.
Zekri J, Ahmed N, Coleman RE, et al. 2001. The skeletal metastatic com-
pications of renal cell carcinoma. Int J Oncol, 19:379–82.
Zometa® [package insert]. 2006. East Hanover, NJ; Novartis Pharmaceu-
ticals Corporation.